Review article: Stem cell therapies for inflammatory bowel disease - Efficacy and safety

Alimentary Pharmacology and Therapeutics

Volumn 32, Issue 8, 2010, Pages 939-952

  Garcia Bosch O ^a   Ricart, E ^a   Panes J ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MELPHALAN; METHOTREXATE; RITUXIMAB; THALIDOMIDE; THIOTEPA; THYMOCYTE ANTIBODY; TREOSULFAN;

CROHN DISEASE; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MEDLINE; MESENCHYMAL STEM CELL TRANSPLANTATION; MORTALITY; NONHUMAN; NONMYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION; REVIEW; SAFETY; THERAPY EFFECT; TREATMENT INDICATION; ULCERATIVE COLITIS;

ADULT; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 77957221364     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04439.x     Document Type: Review

References (62)

1. Peyrin-Biroulet L, Loftus EV Jr., Colombel JF, Sandborn WJ. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 2010 105: 289 297.
2. Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007 25: 2739 2749. (Pubitemid 350127858)
3. Dominici M, Le BK, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006 8: 315 317. (Pubitemid 44269669)
4. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008 8: 726 736.
5. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999 284: 143 147. (Pubitemid 29282067)
6. Dazzi F, van Laar JM, Cope A, Tyndall A. Cell therapy for autoimmune diseases. Arthritis Res Ther 2007 9: 206. (Pubitemid 47382493)
7. Panes J, Salas A. Mechanisms underlying the beneficial effects of stem cell therapies for inflammatory bowel diseases. Gut 2009 58: 898 900.
8. Gonzalez-Rey E, Gonzalez MA, Rico L, Buscher D, Delgado M. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut 2009 58: 929 939.
9. Devine SM, Cobbs C, Jennings M, Bartholomew A, Hoffman R. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 2003 101: 2999 3001. (Pubitemid 36857986)
10. Dwyer RM, Potter-Beirne SM, Harrington KA, et al. Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res 2007 13: 5020 5027.
11. Gratwohl A, Passweg J, Bocelli-Tyndall C, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant 2005 35: 869 879. (Pubitemid 40667629)
12. Kapoor S, Wilson AG, Sharrack B, et al. Haemopoietic stem cell transplantation - an evolving treatment for severe autoimmune and inflammatory diseases in rheumatology, neurology and gastroenterology. Hematology 2007 12: 179 191. (Pubitemid 46930244)
13. Marmont AM. Immunoablation followed or not by hematopoietic stem cells as an intense therapy for severe autoimmune diseases. New perspectives, new problems. Haematologica 2001 86: 337 345.
14. Nash RA, McSweeney PA, Crofford LJ, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 2007 110: 1388 1396.
15. Burt RK, Marmont A, Oyama Y, et al. Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens. Arthritis Rheum 2006 54: 3750 3760. (Pubitemid 44955875)
16. Farge D, Labopin M, Tyndall A, et al. Autologous hematopoietic stem cell transplantation (HSCT) for autoimmune diseases: an observational study on 12 years of experience from the European Group for Blood and Marrow Transplantation (EBMT) Working Party on Autoimmune Diseases. Haematologica 2010 95: 284 292.
17. Oyama Y, Barr WG, Statkute L, et al. Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis. Bone Marrow Transplant 2007 40: 549 555. (Pubitemid 47382125)
18. Vonk MC, Marjanovic Z, van den Hoogen FH, et al. Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis 2008 67: 98 104.
19. Loh Y, Oyama Y, Statkute L, et al. Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used. Blood 2007 109: 2643 2648. (Pubitemid 46425915)
20. Burt RK, Traynor A, Statkute L, et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 2006 295: 527 535. (Pubitemid 43200347)
21. Jayne D, Passweg J, Marmont A, et al. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus 2004 13: 168 176. (Pubitemid 38478643)
22. Rocca MA, Mondria T, Valsasina P, et al. A three-year study of brain atrophy after autologous hematopoietic stem cell transplantation in rapidly evolving secondary progressive multiple sclerosis. AJNR Am J Neuroradiol 2007 28: 1659 1661. (Pubitemid 47598135)
23. Burt RK, Loh Y, Cohen B, et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol 2009 8: 244 253.
24. Veny M, Esteller M, Ricart E, et al. Late Crohn's disease patients present an increase in peripheral Th17 cells and cytokine production compared with early patients. Aliment Pharmacol Ther 2010 31: 561 572.
25. Couri CE, Oliveira MC, Stracieri AB, et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2009 301: 1573 1579.
26. Burt RK, Oyama Y, Verda L, et al. Induction of remission of severe and refractory rheumatoid arthritis by allogeneic mixed chimerism. Arthritis Rheum 2004 50: 2466 2470. (Pubitemid 39062706)
27. Nash RA, McSweeney PA, Nelson JL, et al. Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis. Arthritis Rheum 2006 54: 1982 1986.
28. Verda L, Kim DA, Ikehara S, et al. Hematopoietic mixed chimerism derived from allogeneic embryonic stem cells prevents autoimmune diabetes mellitus in NOD mice. Stem Cells 2008 26: 381 386. (Pubitemid 351413598)
29. Drakos PE, Nagler A, Or R. Case of Crohn's disease in bone marrow transplantation. Am J Hematol 1993 43: 157 158. (Pubitemid 23144283)
30. Lopez-Cubero SO, Sullivan KM, McDonald GB. Course of Crohn's disease after allogeneic marrow transplantation. Gastroenterology 1998 114: 433 440.
31. Ditschkowski M, Einsele H, Schwerdtfeger R, et al. Improvement of inflammatory bowel disease after allogeneic stem-cell transplantation. Transplantation 2003 75: 1745 1747. (Pubitemid 36629161)
32. Talbot DC, Montes A, Teh WL, Nandi A, Powles RL. Remission of Crohn's disease following allogeneic bone marrow transplant for acute leukaemia. Hosp Med 1998 59: 580 581. (Pubitemid 128724373)
33. Castro J, Bentch H, Smith L, et al. Prolonged clinical remission in patients with inflammatory bowel disease (IBD) after high dose chemotherapy (HDC) and autologous blood stem cell transplantation. Blood 1996 88 (Supplement 133A.
34. Kashyap A, Forman SJ. Autologous bone marrow transplantation for non-Hodgkin's lymphoma resulting in long-term remission of coincidental Crohn's disease. Br J Haematol 1998 103: 651 652. (Pubitemid 28545297)
35. Musso M, Porretto F, Crescimanno A, et al. Crohn's disease complicated by relapsed extranodal Hodgkin's lymphoma: prolonged complete remission after unmanipulated PBPC autotransplant. Bone Marrow Transplant 2000 26: 921 923.
36. Soderholm JD, Malm C, Juliusson G, Sjodahl R. Long-term endoscopic remission of crohn disease after autologous stem cell transplantation for acute myeloid leukaemia. Scand J Gastroenterol 2002 37: 613 616. (Pubitemid 34522929)
37. Anumakonda V, Hayee B, Chung-Faye G. Remission and relapse of Crohn's disease following autologous haematopoietic stem cell transplantation for non-Hodgkin's lymphoma. Gut 2007 56: 1325. (Pubitemid 47300443)
38. Marti JL, Mayordomo JI, Isla MD, et al. PBSC autotransplant for inflammatory bowel disease (IBD): a case of ulcerative colitis. Bone Marrow Transplant 2001 28: 109 110. (Pubitemid 32707628)
39. Sonwalkar SA, James RM, Ahmad T, et al. Fulminant Crohn's colitis after allogeneic stem cell transplantation. Gut 2003 52: 1518 1521. (Pubitemid 37176735)
40. Craig RM, Traynor A, Oyama Y, Burt RK. Hematopoietic stem cell transplantation for severe Crohn's disease. Bone Marrow Transplant 2003 32 (Suppl 1 S57 9. (Pubitemid 36546828)
41. Oyama Y, Craig RM, Traynor AE, et al. Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology 2005 128: 552 563. (Pubitemid 40585356)
42. Cassinotti A, Annaloro C, Ardizzone S, et al. Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease. Gut 2008 57: 211 217. (Pubitemid 351158049)
43. Scime R, Cavallaro AM, Tringali S, et al. Complete clinical remission after high-dose immune suppression and autologous hematopoietic stem cell transplantation in severe Crohn's disease refractory to immunosuppressive and immunomodulator therapy. Inflamm Bowel Dis 2004 10: 892 894. (Pubitemid 39545234)
44. Kreisel W, Potthoff K, Bertz H, et al. Complete remission of Crohn's disease after high-dose cyclophosphamide and autologous stem cell transplantation. Bone Marrow Transplant 2003 32: 337 340. (Pubitemid 36927088)
45. Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009 361: 2033 2045.
46. Fang B, Song YP, Liao LM, Han Q, Zhao RC. Treatment of severe therapy-resistant acute graft-versus-host disease with human adipose tissue-derived mesenchymal stem cells. Bone Marrow Transplant 2006 38: 389 390. (Pubitemid 44241551)
47. Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002 30: 42 8. (Pubitemid 34059216)
48. Ortiz LA, Gambelli F, McBride C, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci U S A 2003 100: 8407 8411. (Pubitemid 36842558)
49. Fang B, Shi M, Liao L, et al. Systemic infusion of FLK1(+) mesenchymal stem cells ameliorate carbon tetrachloride-induced liver fibrosis in mice. Transplantation 2004 78: 83 8. (Pubitemid 38938288)
50. Togel F, Weiss K, Yang Y, et al. Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. Am J Physiol Renal Physiol 2007 292: F1626 35. (Pubitemid 46701891)
51. Zappia E, Casazza S, Pedemonte E, et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005 106: 1755 1761. (Pubitemid 41208591)
52. Urban VS, Kiss J, Kovacs J, et al. Mesenchymal stem cells cooperate with bone marrow cells in therapy of diabetes. Stem Cells 2008 26: 244 253.
53. Gonzalez MA, Gonzalez-Rey E, Rico L, Buscher D, Delgado M. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology 2009 136: 978 989.
54. Koc ON, Day J, Nieder M, et al. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 2002 30: 215 222. (Pubitemid 35023593)
55. Horwitz EM, Gordon PL, Koo WK, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci U S A 2002 99: 8932 8937.
56. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008 371: 1579 1586. (Pubitemid 351626841)
57. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004 363: 1439 1441. (Pubitemid 38586721)
58. Larghero J, Farge D, Braccini A, et al. Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis. Ann Rheum Dis 2008 67: 443 449. (Pubitemid 351498421)
59. Garcia-Olmo D, Garcia-Arranz M, Herreros D, et al. A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum 2005 48: 1416 1423. (Pubitemid 40933870)
60. Garcia-Olmo D, Herreros D, Pascual I, et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum 2009 52: 79 86.
61. Onken JE, Gallup D, Hanson J, et al. Successful outpatient treatment of refractory Crohn's disease using adult mesenchymal stem cells. ACG 2006 Final Program Book 2006: 121.
62. Duijvestein M, Wildenberg ME, Vos ACW, et al. Phase I results of intravenous autologous bone marrow derived mesenchymal stromal cell treatment in refractory Crohn's disease. J Crohn's & Colitis 2010 4: S6.